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Lessons learnedBone marrow‐derived cells contribute to tissue repair.Traffic of hematopoietic stem/progenitor cells (HSPCs) is impaired in diabetes.This study tested whether HSPCs mobilization with plerixafor improved the healing of ischemic diabetic wounds.Successful HSPC mobilization with plerixafor did not improve healing of ischemic diabetic wounds.Mobilization of diabetic HSPCs might exert adverse effects on tissue repair. Significance statementThe role of hematopoietic stem cells in diabetic complications is well characterized. In the setting of limb ischemia, cell therapy trials with a variety of cell products yielded variable results. There is an unmet need for therapies for the diabetic foot syndrome beyond the state of the art. This study has hypothesized that the CXCR4 antagonist plerixafor could be repurposed to treat ischemic diabetic wounds. In this phase IIa clinical trial, successful stem cell mobilization with plerixafor did not improve healing of ischemic diabetic wounds. Contrary to what was expected, mobilization of diabetic stem cells might exert adverse effects on tissue repair.

1. INTRODUCTION {#sct312720-sec-0003}
===============

Impaired healing of diabetic wounds is due to a combination of atherosclerosis obliterans, local microangiopathy, neuropathy, and infection.[^1^](#sct312720-bib-0001){ref-type="ref"} The resulting diabetic foot syndrome is a devastating complication, driving morbidity and mortality. Despite surgical treatments and advanced medications, many patients undergo amputations, highlighting the need for additional therapies.[^2^](#sct312720-bib-0002){ref-type="ref"}

Diabetes impairs tissue repair, at least in part by altering stem cell biology. Hematopoietic stem/progenitor cells (HSPCs) are reduced in the peripheral blood (PB) of patients with diabetes.[^3^](#sct312720-bib-0003){ref-type="ref"} Shortage of PB‐HSPCs has been attributed to impaired mobilization from the bone marrow (BM),[4](#sct312720-bib-0004){ref-type="ref"}, [5](#sct312720-bib-0005){ref-type="ref"} a condition deemed mobilopathy.[^6^](#sct312720-bib-0006){ref-type="ref"} The diabetic BM is characterized by inflammation, neuropathy, and microvascular remodeling,[7](#sct312720-bib-0007){ref-type="ref"}, [8](#sct312720-bib-0008){ref-type="ref"} which are more profound in patients with limb ischemia.[9](#sct312720-bib-0009){ref-type="ref"}, [10](#sct312720-bib-0010){ref-type="ref"} In addition to impairing HSPC mobilization from the BM to PB, diabetes hampers the traffic of BM‐derived cells to sites of delayed wound healing.[^11^](#sct312720-bib-0011){ref-type="ref"} Among patients with diabetes, those with lower PB‐HSPCs display a worse outcome of micro‐ and macrovascular complications.[12](#sct312720-bib-0012){ref-type="ref"}, [13](#sct312720-bib-0013){ref-type="ref"} This set of notions suggest that increasing the levels of circulating HSPCs could counter diabetic complications.[^14^](#sct312720-bib-0014){ref-type="ref"}

Granulocyte‐colony stimulating factor (G‐CSF) is most commonly used to mobilize HSPCs, and it might be useful as adjunctive therapy for diabetic wound healing.[^15^](#sct312720-bib-0015){ref-type="ref"} However, the HSPC mobilizing capacity of G‐CSF is significantly compromised by diabetes.[5](#sct312720-bib-0005){ref-type="ref"}, [16](#sct312720-bib-0016){ref-type="ref"} On the other hand, the CXCR4 antagonist plerixafor induces rapid and effective HSPC mobilization in patients with diabetes as in nondiabetic controls.[^17^](#sct312720-bib-0017){ref-type="ref"} Plerixafor is a small chemical approved for HSPC mobilization in myeloma and lymphoma. By blocking interaction of the chemokine CXCL12 with its receptor CXCR4, plerixafor desensitizes HSPCs to the intrinsically high levels of CXCL12 that keep them attached to the BM stroma.[^18^](#sct312720-bib-0018){ref-type="ref"} The resulting surge of PB‐HSPCs is rapid and transient because once plerixafor is cleared, CXCR4 again senses CXCL12 levels and HSPCs return to the BM or home where CXCL12 concentrations are high. Because tissue ischemia stimulates the release of CXCL12, that guides homing of BM‐derived cells,[^19^](#sct312720-bib-0019){ref-type="ref"} we hypothesized that HSPCs mobilized by plerixafor could reach ischemic wounds and aid healing. In diabetic mice, plerixafor was able to mobilize stem/progenitor cells and improved wound healing,[20](#sct312720-bib-0020){ref-type="ref"}, [21](#sct312720-bib-0021){ref-type="ref"} supporting a potential repurposing of this drug for the treatment of diabetic wounds. Therefore, we designed a clinical trial to test the effects of HSPC mobilization with plerixafor on healing of ischemic diabetic wounds.

2. MATERIALS AND METHODS {#sct312720-sec-0004}
========================

2.1. Study design {#sct312720-sec-0005}
-----------------

This was a pilot, phase IIa (repurposing), single‐center, randomized, double‐blind, placebo‐controlled trial. The study protocol is registered on [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT02790957) and complies with the CONSORT (CONsolidated Standards of Reporting Trials) statement and checklist.[^22^](#sct312720-bib-0022){ref-type="ref"} The protocol was approved by the Ethical Committee of the University Hospital of Padova (no. 3694/Ao/15).

2.2. Participants {#sct312720-sec-0006}
-----------------

Patients were recruited from June 2016 to April 2019 at the University Hospital of Padova, Italy. All consecutive patients with diabetes presenting at the inpatient or outpatient clinics with signs of ischemic wound(s) were screened for eligibility. Inclusion criteria were as follows: a diagnosis of type 1 or type 2 diabetes; age 18‐85 years for men or postmenopausal status (cessation of menstrual periods for at least 12 consecutive months) and age ≤85 for women; presence of neuroischemic or ischemic diabetic wound(s) of the foot(s) with a Texas University Classification (TUC) grade 2 or 3, C or D (with ischemia and with or without infection)[^23^](#sct312720-bib-0023){ref-type="ref"}; and ability to provide informed consent. Ischemia was defined in the presence of hemodynamically significant stenosis of limb arteries upon ultrasound examination or angiography, with transcutaneous oxygen tension (TcO~2~) \<50 mmHg and/or ankle‐brachial index (ABI) \<0.9.[^24^](#sct312720-bib-0024){ref-type="ref"} Exclusion criteria were as follows: ongoing sepsis; dialysis; severe chronic kidney disease (defined as an estimated glomerular filtration rate \[eGFR\] \<20 mL/minute/1.73 m^2^); advanced liver disease (defined as cirrhosis or liver enzyme elevation \>3 times the upper limit of normality); clinically relevant abnormalities in white blood cell counts at baseline (eg, leukopenia or thrombocytopenia); hematologic disorders (lymphoma, myeloma, acute or chronic leukemia, chronic myeloproliferative disorders); known or highly suspected solid cancer; women with childbearing potential; known hypersensitivity to plerixafor or its excipients; or inability to provide informed consent.

2.3. Clinical data collection {#sct312720-sec-0007}
-----------------------------

For all patients, we recorded the following information. Demographics and anthropometrics: age, sex, duration of diabetes, weight, height, and body mass index. Prevalence of concomitant conditions: arterial hypertension (defined as a blood pressure level of 140/90 mmHg or higher or use of blood pressure‐lowering drugs); dyslipidemia (defined as a total cholesterol level \>200 mg/dL or a triglycerides level \>150 mg/dL or use of lipid‐lowering drugs); smoking status (defined as habitual smoking of one or more cigarettes per day); coronary artery disease (defined as a past history of acute coronary syndrome or coronary revascularization); cerebrovascular disease (defined as a past history of cerebral ischemia or evidence of carotid artery atherosclerosis); diabetic retinopathy (defined according to the Early Treatment of Diabetic Retinopathy Study[^25^](#sct312720-bib-0025){ref-type="ref"}); somatic or autonomic neuropathy (defined using the Michigan neuropathy screening instrument[^26^](#sct312720-bib-0026){ref-type="ref"} and cardiovascular autonomic tests, respectively); chronic kidney disease (defined as an eGFR of \<60 mL/minute/1.73 m^2^). We also recorded the following laboratory test results, all performed at the same core laboratory of the University Hospital of Padova: HbA1c, complete blood cell count and lymphocyte immunophenotype (CD3, CD4, CD8, CD16, CD56), HbA1c, serum creatinine (eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD‐EPI\] equation[^27^](#sct312720-bib-0027){ref-type="ref"}), urinary albumin/creatinine ratio, and lipid profile (total cholesterol, high‐density lipoprotein cholesterol, triglycerides); low‐density lipoproteins were calculated using the Friedewald equation.[^28^](#sct312720-bib-0028){ref-type="ref"} We recorded all details on ongoing medications for the treatment of diabetes and of concomitant cardiovascular disease and risk factors.

2.4. Wound characterization {#sct312720-sec-0008}
---------------------------

Each patient\'s wound was evaluated clinically for anatomical location, area, depth, ischemia, and infection. Wound size was quantified by taking digital photos of the wound with a caliper; area was then calculated using ImageJ 1.8 (NIH, Bethesda, Maryland). Wound depth was determined using a blunt probe and the probe‐to‐bone maneuver. Infection was suspected by clinical signs (eg, purulent exudate or smell) and confirmed with microbiological culture test. Ischemia was evaluated by TcO~2~ and ABI. TcO~2~ was quantified with TCM400 (De Mori, Milan, Italy), placing the probe closest to the wound, in an area free of edema. ABI was determined using standard automatic sphygmomanometer cuffs (Meteda Srl, San Benedetto del Tronto, Italy) placed at the level of the left arm and ankle homolateral to the wound. When more than one wound was present in the same patient, the wound with the most severe grade was chosen as the index wound.

2.5. Randomization and treatment {#sct312720-sec-0009}
--------------------------------

After signing written informed consent, patients were randomized 1:1 to treatment with plerixafor or placebo, based on a computer‐generated sequence not available to study staff. To allow for a balanced distribution of patients in the two arms at interim analysis (see below), the randomization sequence had two equally distributed blocks. Concealment was guaranteed by the closed envelope system. Once a patient was ready to be randomized, the allocation envelope was opened by the investigator and the patient was irrevocably randomized to the indicated allocation. Patients, study staff, and care providers remained blinded to the assigned treatment for the entire duration of the study. Patients\' follow‐up and outcome assessment was performed by staff members who were blinded to the treatment.

At 8:00 [am]{.smallcaps} of the day of treatment, a blood sample was drawn for complete blood cell count and quantification of circulating stem/progenitor cells. Then, the patient received a subcutaneous injection of plerixafor 0.24 mg/kg or matching volume of 0.9% saline (placebo). The injection was prepared by personnel not involved in patient care. Plerixafor and saline injections looked identical. At 2:00 [pm]{.smallcaps}, a second blood sample was drawn to evaluate stem/progenitor cell mobilization. Contrary to what was done in most cell therapy trials for peripheral arterial disease,[^29^](#sct312720-bib-0029){ref-type="ref"} we did not limit to patients who could not undergo revascularization (no‐option), because lack of blood supply was considered a limiting factor for HSPC homing to the wound. In addition to plerixafor or placebo, all patients received standard of care with medical and surgical therapy, including vasodilators, antibiotics, advanced medications, negative pressure, surgical debridement, and revascularization, as deemed appropriate. For wounds on a weight‐bearing surface, offloading was achieved with removable cast walkers, fore/rear‐foot offloading shoes, custom shoes, or non‐weight‐bearing strategies, according to individual patient characteristics and needs. If the patient was scheduled for revascularization (surgical or endovascular), study treatment had to be performed within 72 hours after revascularization, to benefit from the expectedly high CXLC12 expression in the (hitherto) ischemic tissue.

2.6. Follow‐up and outcome definitions {#sct312720-sec-0010}
--------------------------------------

Study participation did not interfere with routine clinical management of the patients, who were seen at intervals dictated by wound and patient characteristics, adapted over time based on healing trends. For the purpose of the study, patients were scheduled for the first follow‐up visit 1 week after treatment and then every month after treatment until wound healing, death, or completion of the maximum 6‐month follow‐up period. An intention‐to‐treat approach was used and only the first follow‐up was obliged to retain the patient in the analysis. Wound characteristics were reassessed as each visit. When one or more visits were missing, the healing status was updated at the next available visit or the patient was censored if no further visit was available.

The primary outcome was complete wound healing, defined as a TUC grade 0 (complete re‐epithelization), independently of the residual presence of ischemia or closed infection. Secondary outcomes were the changes over time in wound size, TcO~2~, and ABI; the need for minor or major amputations; and the comparison of CD34^+^ stem cell mobilization 6 hours after plerixafor administration in patients with good outcome vs those with poor outcome. At each follow‐up visit, patients were also evaluated for the occurrence of eventual adverse events (AEs).

2.7. Stem/progenitor cell quantification {#sct312720-sec-0011}
----------------------------------------

Quantification of HSPCs was performed using flow cytometry on fresh blood cells as previously described in detail.[^12^](#sct312720-bib-0012){ref-type="ref"} Briefly, after red blood cell lysis, cells were stained with monoclonal antibodies against human CD133 (Miltenyi Biotech, Bergisch Gladbach, Germany), CD34, CD45 (Becton, Dickinson and Company, Franklin Lakes, New Jersey), and KDR (R&D Systems, Minneapolis, Minnesota). After gating mononuclear cells in the morphologic gate, cells were examined for expression of CD34. CD45 diminished staining was used to confirm HSPC identity. At least 500 000 events were acquired. The absolute HSPC count per milliliter of blood was retrieved by multiplying the frequency of CD34+ cells over 1 million events by the white blood cell count (×1000 per microliter). The same trained operator performed all analyses throughout the study.

2.8. Sample size estimation {#sct312720-sec-0012}
---------------------------

No prior study could be used to derive a prespecified effect size. In a recent cohort of 52 patients with a median TUC stage 3 wound at our center, the rate of complete healing after a median 3‐month follow‐up was 40.4%.[^30^](#sct312720-bib-0030){ref-type="ref"} Because all patients enrolled in the present study had ischemia, we allowed for a longer observation time, setting the primary endpoint evaluation at 6 months. We calculated that, with n = 20 patients per group, the study would have 80% power to detect a threefold higher chance of healing in plerixafor‐treated patients vs controls (60% vs 20%).[^31^](#sct312720-bib-0031){ref-type="ref"} To account for a dropout rate \<15%, we planned to recruit a maximum of 46 patients.

Plerixafor is approved for HSPC mobilization in lymphoma and myeloma and has never been used before in patients with diabetes with ischemic wounds. Thus, for safety reasons, we planned an interim analysis once the follow‐up of 50% of the target number of patients was completed (n = 23). The protocol imposed study termination in case the interim analysis showed a lower probability of achieving the primary endpoint (complete wound healing) in the plerixafor group with a *P* value \<.10.

2.9. Statistical analysis {#sct312720-sec-0013}
-------------------------

For descriptive purposes, continuous variables are reported as mean and SD, whereas categorical variables are reported as percentage. Normality of continuous variables were checked using the Shapiro‐Wilk test and non‐normal variables were log‐transformed before analysis. Comparisons between the two treatment groups were performed using two‐tail unpaired Student\'s *t* test for continuous variables and chi‐square test for categorical variables. The Hochberg method was used to adjust for multiplicity of testing. For the primary endpoint, wound healing rates at 6 months were compared between groups using the chi‐square test. To account for time‐dependency of the event, in a separate analysis, we used the Cox proportional hazards regression model. The between‐group comparisons in the change over time of wound size, TcO~2~, and ABI were performed using the mixed model for repeated measures, considering the treatment group, time, and time × group interaction. The rate of amputations was analyzed using Cox regression. HSPC mobilization was within each group using two‐tail paired Student\'s *t* test; the ratio between post‐plerixafor and baseline HSPC levels were compared between patients treated with plerixafor, according to their meeting the primary endpoint. SPSS version 23 was used. Statistical significance was accepted at *P* \< .05.

3. RESULTS {#sct312720-sec-0014}
==========

3.1. Patient disposition and characteristics {#sct312720-sec-0015}
--------------------------------------------

The study flowchart is shown in Figure [1](#sct312720-fig-0001){ref-type="fig"}. From June 2016 to April 2019, a total of 52 patients were screened; 26 were excluded for the following reasons: mistiming of revascularization (n *=* 10), lack of significant ischemia (n *=* 7), hematological disorders (n *=* 4), severe renal or hepatic dysfunction (n *=* 2), solid cancer (n *=* 1), or consent denial (n *=* 2).

![Study flowchart](SCT3-9-965-g001){#sct312720-fig-0001}

An interim analysis was performed once the follow‐up of the first 23 patients was completed. Four of the 12 patients who received plerixafor vs 9 of the 11 patients who received placebo achieved complete wound healing (chi‐square *P* = .019). This was equal to a relative risk of nonhealing of 2.45 (95% confidence interval 1.05‐5.73) and a 49% absolute lower risk of healing in the plerixafor group. Based on such analysis, the study was terminated. While follow‐up of patients included in the interim analysis was being completed, three more patients were enrolled. Thus, the final analysis data set was composed of 26 patients, equally distributed in the two groups (13/13). Clinical characteristics of study patients are summarized in Table [1](#sct312720-tbl-0001){ref-type="table"}. Patients (84.6% males) were on average 69 years of age and had diabetes for \~15 years. Despite randomization, diabetes duration was longer in the plerixafor group, although such difference was not significant after adjusting for multiple testing. All enrolled patients had hemodynamically significant stenosis of leg arteries combined with a TcO~2~ \<50 mmHg and/or ABI \<0.9. Prior to randomization and treatment, surgical debridement was performed in all cases and most patients had underwent revascularization (69.2% in the plerixafor group and 76.9% in the placebo group).

###### 

Patient characteristics

  Characteristics                  All patients (n = 26)   Placebo (n = 13)      Plerixafor (n = 13)   *P* value
  -------------------------------- ----------------------- --------------------- --------------------- ------------------------------------------------
  Demographics                                                                                         
  Sex male, %                      84.6                    84.6                  84.6                  1.000
  Age, years                       69.2 ± 8.5              72.2 ± 8.5            66.3 ± 7.7            .078
  Diabetes duration, years         14.7 ± 12.1             9.9 ± 11.9            19.5 ± 10.6           .039[^a^](#sct312720-note-0002){ref-type="fn"}
  Risk factors                                                                                         
  BMI, kg/m^2^                     28.4 ± 4.5              27.2 ± 4.8            29.5 ± 4.0            .193
  Hypertension, %                  100.0                   100.0                 100.0                 1.000
  Systolic blood pressure, mmHg    132.3 ± 15.4            134.6 ± 17.6          129.9 ± 13.1          .449
  Diastolic blood pressure, mmHg   72.7 ± 7.8              75.0 ± 8.4            70.4 ± 6.6            .133
  Dyslipidemia, %                  80.8                    76.9                  84.6                  .635
  Current smoke, %                 26.9                    38.5                  15.4                  .165
  Complications                                                                                        
  Coronary artery disease, %       53.8                    61.5                  46.2                  .452
  Carotid atherosclerosis, %       84.6                    76.9                  92.3                  .296
  Retinopathy, %                   50.0                    38.5                  61.5                  .257
  Neuropathy, %                    69.2                    53.8                  84.6                  .096
  Chronic kidney disease, %        34.6                    30.8                  38.5                  .695
  Stroke/TIA, %                    7.7                     7.7                   7.7                   1.000
  Prior revascularization, %       73.1                    76.9                  69.2                  .674
  Blood exams                                                                                          
  HbA1c, % (mmol/mol)              9.2 ± 2.1 (75 ± 17)     9.0 ± 2.0 (73 ± 16)   9.4 ± 2.3 (77 ± 19)   .677
  Serum creatinine, μmol/L         110.0 ± 52.4            98.1 ± 44.8           121.8 ± 58.4          .255
  eGFR, mL/min/1.73 m^2^           65.2 ± 24.3             69.9 ± 24.0           60.5 ± 24.7           .331
  Albumin/creatinine ratio, mg/g   357.5 ± 845.4           279.0 ± 730.1         442.5 ± 981.2         .639
  Total cholesterol, mg/dL         136.1 ± 42.9            131.9 ± 49.5          140.3 ± 36.8          .628
  HDL cholesterol, mg/dL           36.9 ± 13.1             35.7 ± 11.5           38.1 ± 14.9           .652
  LDL cholesterol, mg/dL           74.8 ± 36.1             71.8 ± 43.9           77.8 ± 27.6           .678
  Triglycerides, mg/dL             127.5 ± 51.6            127.2 ± 56.7          127.8 ± 48.3          .976
  Therapies                                                                                            
  Statin, %                        65.4                    61.5                  69.2                  .695
  RAS blockers, %                  65.4                    69.2                  61.5                  .695
  Other BP‐lowering drugs, %       92.3                    100.0                 84.6                  .153
  APA, %                           88.5                    92.3                  84.6                  .558
  Insulin, %                       76.9                    61.5                  92.3                  .067
  Metformin, %                     23.1                    30.8                  15.4                  .372
  DPP‐4 inhibitors, %              7.7                     15.4                  0.0                   .153
  SGLT‐2 inhibitors, %             3.8                     7.7                   0.0                   .327
  Sulphonylurea, %                 11.5                    7.7                   15.4                  .558
  Wound characteristics                                                                                
  TUC II/III, n                    3/23                    1/12                  2/10                  .652
  TcO~2~, mmHg                     46.0 ± 14.9             46.5 ± 17.1           45.6 ± 12.9           .888
  ABI                              1.00 ± 0.21             0.96 ± 0.23           1.06 ± 0.19           .304

Abbreviations: ABI, ankle‐brachial index; APA, antiplatelet agents; BMI, body mass index; BP, blood pressure; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; RAS, renin angiotensin system; SGLT‐2, sodium‐glucose cotransporter‐2; TcO~2~, transcutaneous oxygen tension; TIA, transient ischemic attack; TUC, Texas University Classification.

Not significant after adjusting for multiple testing.

3.2. Wound healing {#sct312720-sec-0016}
------------------

The median (interquartile range) follow‐up was 4.3 (3.3‐5.9) months in the plerixafor group and 3.9 (2.7‐4.1) months in the placebo group. The rate of complete wound healing was 38.5% (5/13 patients) in the plerixafor group vs 69.2% (9/13 patients) in the placebo group (chi‐square *P* = .115). To account for the time‐dependency of the event, we evaluated Kaplan‐Meier curves (Figure [2A](#sct312720-fig-0002){ref-type="fig"}) and the log‐rank *P* value was .147.

![Study outcomes. A, The primary endpoint (complete wound healing). B, A modified healing endpoint (not specified in the original protocol). A, B, D, Time is shown in days because categorical events were recorded at given day after treatment; *P* values were obtained from the log‐rank test. C, E, F, Time is shown in weeks because continuous variables were averaged at the prespecified follow‐up time point; *P* values were obtained from the mixed model for repeated measures. TcO~2~, transcutaneous oxygen tension](SCT3-9-965-g002){#sct312720-fig-0002}

Because it was difficult to distinguish between complete healing (grade 0) and superficial wounds (grade 1A) when scars were present, we explored a modified definition of the primary endpoint, which was not specified in the protocol (ie, achieving a grade 0‐1A wound). With this exploratory definition, wound outcome still tended to be worse in the plerixafor vs the placebo group (log‐rank *P* = .124; Figure [2B](#sct312720-fig-0002){ref-type="fig"}).

3.3. Secondary outcomes {#sct312720-sec-0017}
-----------------------

Because the study was terminated prematurely and the primary endpoint was not met, the analysis of all secondary outcomes must be considered exploratory.

On average, relative wound size remained larger in the plerixafor group compared with the placebo group. According to the mixed model for repeated measures, the two curves were not significantly different (*P* = .072; Figure [2C](#sct312720-fig-0002){ref-type="fig"}), but a point‐by‐point analysis showed that wound size was significantly different between groups at 3 months (not significant after multiple testing). Minor amputations were nominally, but not significantly, more frequent in the plerixafor group than in the placebo group (Figure [2D](#sct312720-fig-0002){ref-type="fig"}). The change in TcO~2~ and ABI were not significantly different between groups (Figure [2E](#sct312720-fig-0002){ref-type="fig"},F). ABI values were relatively high, likely as a reflection of uncompressible arteries in a population with a high prevalence of neuropathy, being therefore poorly indicative of the degree of ischemia. ABI values tended to be greater in the plerixafor group, which was significant at 2 months (not significant after multiple testing).

3.4. Stem cell mobilization {#sct312720-sec-0018}
---------------------------

Baseline levels of CD34^+^ HSPCs was 2.3/μL in the plerixafor group and 2.5/μL in the placebo group (*P* = .74). Although HSPC levels remained unchanged from 8.00 [am]{.smallcaps} to 2.00 [pm]{.smallcaps} in the placebo group (fold increase 1.07 ± 0.29; Figure [3A](#sct312720-fig-0003){ref-type="fig"}), the increase was statistically significant in the plerixafor group (fold increase 7.72 ± 4.41; *P* \< .001; Figure [3B,C](#sct312720-fig-0003){ref-type="fig"}), and all patients who received plerixafor achieved a greater than twofold increase in HSPCs compared with baseline. The degree of HSPC mobilization obtained after plerixafor was similar to that obtained in a historical series of 10 younger patients with diabetes without ischemic wounds (7.15 ± 2.23; *P* = .712 vs patients in the present study; Figure [3D](#sct312720-fig-0003){ref-type="fig"}). Among patients who received plerixafor, those who achieved complete wound healing tended to have lower fold‐increase in HSPCs compared with those who did not heal (6.08 ± 1.57 vs 8.76 ± 5.37; *P* = .309).

![Stem cell mobilization. A, B, Levels of CD34^+^ HSPCs at baseline (8:00 [am]{.smallcaps}) and 6 hours after placebo (A) or plerixafor (B) injection. Box and whisker plots illustrate median, interquartile range (box), and range (whiskers). \**P* \< .05 vs 8:00 [am]{.smallcaps} C, Fold‐increase of HSPCs after plerixafor or placebo (\**P* \< .05). D, Fold‐increase of HSPCs after plerixafor in patients with ischemic DFUs of the present study compared with historical diabetic control patients without chronic complications. Ctrl, control; DFU, diabetic foot ulcer; HSPCs, hematopoietic stem/progenitor cells](SCT3-9-965-g003){#sct312720-fig-0003}

3.5. Adverse events {#sct312720-sec-0019}
-------------------

One serious AE (acute coronary syndrome) occurred in one patient randomized to plerixafor, 3 days after injection, and was deemed related to pre‐existing conditions and unrelated to study drug. There were two nonserious AEs: one in a patient randomized to plerixafor (transient flushing after injection) and one in a patient randomized to placebo (petechial rash, that disappeared after aspirin withdrawal).

4. DISCUSSION {#sct312720-sec-0020}
=============

In this phase IIa, double‐blind, randomized, placebo‐controlled trial, successful HSPC mobilization with plerixafor did not improve healing of ischemic diabetic wounds. The trial was terminated because of safety concerns after completing follow‐up of 50% of the target population. The significant adverse effect of plerixafor observed in the interim analysis was not confirmed in the final analysis, but safety concerns remained because all outcomes tended to be worsened by plerixafor.

Interestingly, in response to plerixafor, patients with diabetes with ischemic wounds showed the same HSPC mobilization response as patients with diabetes without chronic complications. This finding demonstrates that although diabetes affects the BM microenvironment and impairs HSPC traffic,[^4^](#sct312720-bib-0004){ref-type="ref"} it does not reduce HSPC bioavailability in the BM, even in the presence of neuropathy and/or vascular complications.

There are several possible explanations for the null results of this trial. First, heterogeneity of patients and of wound characteristics may have masked smaller effects of plerixafor. The degree of ischemia was variable, most patients underwent revascularization, allowing a high healing rate, and patients in the plerixafor group had longer disease duration. Second, plerixafor half‐life is 3‐5 hours and its transient effect on HSPC levels may be insufficient to drive durable benefits needed to improve healing. However, no transient favorable effect was observed at 1 week or 1 month. Third, HSPCs might not have reached ischemic tissues, owing to the impaired expression of the homing cytokine CXCL12 previously noted in experimental diabetic wounds.[32](#sct312720-bib-0032){ref-type="ref"}, [33](#sct312720-bib-0033){ref-type="ref"} Indeed, local re‐expression of CXCL12 has been recently identified as a strategy to promote diabetic wound healing in mice.[^34^](#sct312720-bib-0034){ref-type="ref"}

None of these explanations would, however, justify the adverse effects of plerixafor observed in the interim analysis. Given the small sample size, it is possible that plerixafor exerted no benefit and no harm and that results of the interim analysis occurred by chance. Mechanistic explanations include the inhibition of CXCR4 by plerixafor in the wound, which may worsen endothelial cell migration and tissue healing.[^35^](#sct312720-bib-0035){ref-type="ref"} Alternatively, prior studies have shown that diabetic HSPCs have impaired angiogenic function and differentiation capacity.[36](#sct312720-bib-0036){ref-type="ref"}, [37](#sct312720-bib-0037){ref-type="ref"} A recent double‐blind randomized controlled trial of BM cell therapy for critical limb ischemia showed that the benefit was worse in patients with diabetes than in nondiabetic ones.[^38^](#sct312720-bib-0038){ref-type="ref"} Furthermore, it has been shown that excess migration of CD34^+^ progenitor cells is associated with worse outcomes of patients with diabetes with critical limb ischemia.[^39^](#sct312720-bib-0039){ref-type="ref"} Moreover, we have recently shown that the same signaling pathway causing inflammatory myelopoiesis is also responsible for stem cell mobilopathy in diabetes.[^40^](#sct312720-bib-0040){ref-type="ref"} Based on these literature data, we speculate that plerixafor may have mobilized antiangiogenic or proinflammatory cells exerting detrimental effects on wound healing. Thus, mobilizing HSPCs without countering myelopoiesis might be insufficient to improve diabetes‐related outcomes.

5. CONCLUSION {#sct312720-sec-0021}
=============

Although unsuccessful, this study helps provide a better understanding of the role of stem cells in diabetic complications. The interplay among HSPC function, their traffic, and repair of peripheral tissues is complex. Acting on the downstream processes that drive HSPC mobilization (ie, CXCR4 antagonism) is not a suitable strategy to improve healing of ischemic diabetic wounds. Because adjunctive therapy for the diabetic foot syndrome remains an unmet need, a more comprehensive re‐education of diabetic hematopoiesis should be attempted.
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